Celcuity’s Gedatolisib Doubles Progression-Free Survival in Phase 3 Breast Cancer Trial
MINNEAPOLIS, Minnesota, USA , June 2, 2026 Celcuity has announced groundbreaking results from the Phase 3 VIKTORIA-1 clinical trial,...
ASCO 2026
Advertisement
ImmunityBio Highlights ANKTIVA Data in Lung and Bladder Cancer at ASCO 2026
CULVER CITY, Calif., June 1, 2026 ImmunityBio announced new clinical and comparative data from its ANKTIVA® (nogapendekin alfa inbakicept-pmln)...
Telix Presents Encouraging Phase 3 Results for TLX591-Tx at ASCO 2026
MELBOURNE, Australia & INDIANAPOLIS, U.S., June 2, 2026 Telix Pharmaceuticals announced positive Part 1 data from its global Phase...
Karyopharm Highlights Phase 3 SENTRY Trial Progress in Myelofibrosis
NEWTON, Mass., June 1, 2026 Karyopharm Therapeutics has announced that it will host an investor conference call featuring leading...
Ono’s ONO-4578 Improves Progression-Free Survival in Gastric Cancer Phase 2 Study
OSAKA, Japan, June 2, 2026 Ono Pharmaceutical announced positive Phase 2 clinical trial results for ONO-4578, its investigational oral...
Advertisements
Paradigm Health Advances Oncology Research with SPIRE-Powered ASCO Study
COLUMBUS, Ohio and CHICAGO, June 1, 2026 Paradigm Health has announced the successful implementation of its SPIRE (Scalable Platform...
Greywolf Reports Durable Responses with First-in-Class ERAP1 Inhibitor
OXFORD, UK, May 22, 2026 Greywolf Therapeutics announced encouraging clinical results from the Phase 1b portion of its ongoing...
Avenzo Reports Promising Phase 1 Data for AVZO-021 in HR+ Breast Cancer
SAN DIEGO, Calif., June 1, 2026 Avenzo Therapeutics announced updated clinical results from the Phase 1 portion of its...
SystImmune’s BL-M14D1 Shows Strong Activity in SCLC
REDMOND, Wash., June 1, 2026 SystImmune has reported encouraging Phase 1 clinical data for its investigational DLL3-targeting antibody-drug conjugate...
Protagonist to Showcase Phase 3 VERIFY and Long-Term Rusfertide Data at EHA 2026
NEWARK, Calif., June 1, 2026 Protagonist Therapeutics announced that four abstracts featuring rusfertide in polycythemia vera (PV) will be...
Advertisement
